CervoMed to Participate in Upcoming Investor Conferences
Emerging Growth Conference 69
Format: Q&A Session
Date:
Time:
Webcast Link: click here
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.
Format: Corporate presentation
Date:
Time:
Webcast Link: click here
To learn more about the
23rd Annual
Format: Corporate presentation
Date:
Time:
Webcast Link: click here
Available webcasts will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
Investors@cervomed.com
617-430-7579
Source: CervoMed Inc.